Superior Group of Companies, Inc. was organized in 1920 and incorporated in 1922 as a New York company under the name Superior Surgical Mfg. Co., Inc. In 1998 the company changed its name to Superior Uniform Group, Inc. and redomiciled to Florida. Effective May 3 2018 Superior Uniform Group, Inc. changed its name to Superior Group of Companies, Inc. The company operates through three reportable business segments: Branded Products Healthcare Apparel and Contact Centers.
The…
Superior Group of Companies, Inc. was organized in 1920 and incorporated in 1922 as a New York company under the name Superior Surgical Mfg. Co., Inc. In 1998 the company changed its name to Superior Uniform Group, Inc. and redomiciled to Florida. Effective May 3 2018 Superior Uniform Group, Inc. changed its name to Superior Group of Companies, Inc. The company operates through three reportable business segments: Branded Products Healthcare Apparel and Contact Centers.
The Branded Products segment creates and sells customized merchandising solutions promotional products and branded uniform programs through its own facilities or third party manufacturers. The Healthcare Apparel segment manufactures and sells scrubs lab coats protective apparel and patient apparel mainly to healthcare laundries dealers distributors retailers and consumers. The Contact Centers segment provides outsourced nearshore and onshore business process outsourcing contact center and call center support services to North American customers. Revenue is derived from the sale of these products and services to a diverse set of end users.
The company operates through the following segments: Branded Products Healthcare Apparel and Contact Centers.
• Branded Products segment focuses on creating customized merchandising solutions promotional products and branded uniform programs using the BAMKO and HPI brands. Products are manufactured either in company owned facilities or through third party suppliers. The segment maintains sales offices in the United States Canada and Brazil with additional support functions located in China and India.
• Healthcare Apparel segment produces a wide range of healthcare apparel including scrubs lab coats protective apparel and patient apparel under the Wink Fashion Seal Healthcare CID Resources and Carhartt Medical brands. Manufacturing occurs either in owned facilities or via third party contractors. The segment sells its products primarily to healthcare laundries dealers distributors retailers and consumers mainly in the United States.
• Contact Centers segment delivers outsourced nearshore and onshore business process outsourcing contact center and call center services through The Office Gurus entities. Operations are located in El Salvador Belize Dominican Republic United States and Jamaica. Services are provided to North American customers using English Spanish and bilingual speaking agents.
Branded Products competes with national and regional firms such as BDA Inc HALO Branded Solutions Inc Staples Inc Cimpress PLC HH Global Group Limited Lands End Inc and Workwear Outfitters LLC. The company relies on its creative services product development proprietary web technology global sourcing network and strong brands to maintain a competitive edge. Healthcare Apparel faces competitors including Medline Industries Inc Careismatic Brands Barco Uniforms Inc FIGS Inc Encompass Medical and Standard Textile Co Inc. Superior leverages its brand strength product quality and marketing capabilities to compete effectively. The Contact Centers market is highly fragmented with competitors ranging from small niche providers to large global players such as TaskUs Inc Transparent BPO Concentrix + Webhelp Focus Services LLC Ubiquity CCI and RDI. The company differentiates itself through its nearshore delivery model multilingual workforce and focus on high quality service.
Branded Products serves customers across retail chain food service entertainment technology transportation and other industries. Healthcare Apparel serves healthcare laundries dealers distributors retailers and consumers primarily in the United States. Contact Centers provides services to North American businesses seeking outsourced contact center and back office support.
Sectors:Consumer Discretionary · IndustrialsSector rationaleThe company's primary revenue drivers are the Branded Products and Healthcare Apparel segments, which design and manufacture customized merchandising, promotional products, and medical scrubs/apparel sold to retailers and consumers. The Contact Centers segment provides outsourced business process outsourcing (BPO) and call center services, which falls under the 'Consulting' or 'Facility Services' categories within the Industrials sector.Industries:ApparelConsumer DiscretionaryPrimaryThe company's Healthcare Apparel segment manufactures and sells scrubs, lab coats, protective apparel, and patient apparel under brands like Wink and Fashion Seal. Additionally, the Branded Products segment creates branded uniform programs, fitting the design and manufacture of apparel and textiles.Facility ServicesIndustrialsSecondaryThe Contact Centers segment provides outsourced business process outsourcing (BPO), contact center, and call center support services to North American customers through The Office Gurus entities.Classified using BQ-MICSCIK: 0000095574
Investment Thesis
▲ Bull case
SGC is executing a proven strategic playbook by leveraging its redundant manufacturing and sourcing strategy to navigate tariff-driven disruptions, positioning itself to gain market share as competitors struggle with supply chain rigidity. Management explicitly highlighted that their long-standing diversification across multiple countries—accelerated since the first Trump administration—allows them to pivot production away from China for most products, with only niche items like electronics and stainless steel drinkware remaining China-dependent. This flexibility is not just defensive but offensive: they are actively recruiting sales reps, winning new accounts, and expanding wallet share, citing a record pipeline in Branded Products and contact centers. The CEO emphasized that during past crises, they gained market share by being agile while others hesitated, and they are replicating this playbook now—evidenced by strong booking trends and upside surprises in the pipeline despite slower deal velocity. The contact center segment, their highest-margin business, grew revenue 3% year-over-year with solid retention and new customer acquisition via their internal sales force, demonstrating resilience in a segment less exposed to direct tariff impacts. Crucially, SGC is not merely weathering the storm but using it to sharpen its competitive edge, with plans to capitalize on market dislocations through opportunistic acquisitions once tariff uncertainty clears, targeting distressed competitors overly reliant on China sourcing. This approach is reinforced by their aggressive share repurchase program—$3.8 million in Q1 alone for ~294,000 shares—signaling management’s conviction that the stock is undervalued relative to its long-term earning power, especially as they reduce annualized SG&A by $13 million starting in Q2 to bolster profitability as demand normalizes. The company’s strong balance sheet, with $20 million in cash and net leverage of 2.2x (well within covenant limits), provides the financial flexibility to invest in growth while returning capital, a dual strategy that has historically driven outperformance during volatile periods.
SGC’s Healthcare Apparel segment, though currently facing headwinds from institutional spending delays and brick-and-mortar wholesale softness, is primed for accelerated growth through strategic digital channel expansion and brand-building investments that are underappreciated by the market. Management acknowledged declining revenue in institutional Healthcare Apparel and brick-and-mortar channels but emphasized ongoing investments in digital wholesale and direct-to-consumer (DTC) platforms to capture growth in a sector where they hold only a single-digit market share—a clear signal of significant runway. They are specifically driving demand for their Wink and Carhartt licensed brands, which combine strong brand equity with margins superior to generic apparel, and are doing so with deliberate precision to avoid overextension. The CEO noted that scrubs, their core product, are less impacted by research funding pullbacks affecting lab coats and protective gear, implying a more stable demand base than commonly perceived. Furthermore, the shift to digital channels reduces reliance on volatile institutional buyers and brick-and-mortar wholesalers, creating a more predictable, scalable revenue stream with higher margins due to lower overhead and direct customer relationships. This digital transformation is not a speculative bet but a continuation of a proven strategy: they referenced past success in pivoting during crises (e.g., COVID) to capture share, and the current investment in DTC and wholesale digital channels is laying the groundwork for a structural shift in how they serve the Healthcare Apparel market. As institutional spending eventually resumes—and it will, given the enduring need for healthcare uniforms—their digital infrastructure will enable faster conversion of demand into sales, potentially triggering a margin-accretive inflection point that the market is overlooking amid near-term volatility. The segment’s gross margin held up relatively well at 37.2% in Q1 (up sequentially), suggesting underlying operational resilience that could expand as digital channels scale and mix improves.
The contact center business, SGC’s highest-margin segment, is undergoing a quiet but transformative upgrade through the deployment of cutting-edge technology that enhances customer experience and operational efficiency—a catalyst management mentioned but did not emphasize enough given its long-term margin expansion potential. While Q1 EBITDA was only slightly below the prior year ($2.8M vs $2.9M), the segment held gross margin flat at 53.6% year-over-year despite SG&A rising 90 basis points due to professional fees, indicating underlying pricing power and cost discipline. More importantly, the CEO highlighted that they are actively testing and utilizing technology to serve high-touch small- and medium-sized enterprises (SMEs), a segment where personalization and responsiveness command premium pricing. This technological edge is not merely defensive; it is enabling them to win RFPs and build a record pipeline through their newly formed internal sales team, directly addressing historical gaps in sales capacity. The ability to integrate advanced CRM, AI-driven routing, and analytics into their service offering allows them to differentiate beyond basic call handling, creating sticky, high-value contracts that are less susceptible to commoditization. As SMEs increasingly outsource customer-facing functions to specialized providers who can deliver both efficiency and empathy, SGC is positioning itself as a preferred partner—leveraging its scale, technology investments, and sales focus to capture share from fragmented, less sophisticated competitors. This segment’s resilience is further underscored by its minimal direct exposure to tariffs (impact is indirect via customer product costs), meaning its growth trajectory is less hostage to macro swings than the Branded Products or Healthcare Apparel segments. With the $13 million in annualized SG&A savings beginning to flow in Q2, the contact center segment’s already strong margins could expand significantly, turning it into a consistent, high-quality earnings driver that the market is undervaluing amid the noise around tariff-sensitive segments.
SGC is executing a proven strategic playbook by leveraging its redundant manufacturing and sourcing strategy to navigate tariff-driven disruptions, positioning itself to gain market share as competitors struggle with supply chain rigidity. Management explicitly highlighted that their long-standing diversification across multiple countries—accelerated since the first Trump administration—allows them to pivot production away from China for most products, with only niche items like electronics and stainless steel drinkware remaining China-dependent. This flexibility is not just defensive but offensive: they are actively recruiting sales reps, winning new accounts, and expanding wallet share, citing a record pipeline in Branded Products and contact centers. The CEO emphasized that during past crises, they gained market share by being agile while others hesitated, and they are replicating this playbook now—evidenced by strong booking trends and upside surprises in the pipeline despite slower deal velocity. The contact center segment, their highest-margin business, grew revenue 3% year-over-year with solid retention and new customer acquisition via their internal sales force, demonstrating resilience in a segment less exposed to direct tariff impacts. Crucially, SGC is not merely weathering the storm but using it to sharpen its competitive edge, with plans to capitalize on market dislocations through opportunistic acquisitions once tariff uncertainty clears, targeting distressed competitors overly reliant on China sourcing. This approach is reinforced by their aggressive share repurchase program—$3.8 million in Q1 alone for ~294,000 shares—signaling management’s conviction that the stock is undervalued relative to its long-term earning power, especially as they reduce annualized SG&A by $13 million starting in Q2 to bolster profitability as demand normalizes. The company’s strong balance sheet, with $20 million in cash and net leverage of 2.2x (well within covenant limits), provides the financial flexibility to invest in growth while returning capital, a dual strategy that has historically driven outperformance during volatile periods.
SGC’s Healthcare Apparel segment, though currently facing headwinds from institutional spending delays and brick-and-mortar wholesale softness, is primed for accelerated growth through strategic digital channel expansion and brand-building investments that are underappreciated by the market. Management acknowledged declining revenue in institutional Healthcare Apparel and brick-and-mortar channels but emphasized ongoing investments in digital wholesale and direct-to-consumer (DTC) platforms to capture growth in a sector where they hold only a single-digit market share—a clear signal of significant runway. They are specifically driving demand for their Wink and Carhartt licensed brands, which combine strong brand equity with margins superior to generic apparel, and are doing so with deliberate precision to avoid overextension. The CEO noted that scrubs, their core product, are less impacted by research funding pullbacks affecting lab coats and protective gear, implying a more stable demand base than commonly perceived. Furthermore, the shift to digital channels reduces reliance on volatile institutional buyers and brick-and-mortar wholesalers, creating a more predictable, scalable revenue stream with higher margins due to lower overhead and direct customer relationships. This digital transformation is not a speculative bet but a continuation of a proven strategy: they referenced past success in pivoting during crises (e.g., COVID) to capture share, and the current investment in DTC and wholesale digital channels is laying the groundwork for a structural shift in how they serve the Healthcare Apparel market. As institutional spending eventually resumes—and it will, given the enduring need for healthcare uniforms—their digital infrastructure will enable faster conversion of demand into sales, potentially triggering a margin-accretive inflection point that the market is overlooking amid near-term volatility. The segment’s gross margin held up relatively well at 37.2% in Q1 (up sequentially), suggesting underlying operational resilience that could expand as digital channels scale and mix improves.
The contact center business, SGC’s highest-margin segment, is undergoing a quiet but transformative upgrade through the deployment of cutting-edge technology that enhances customer experience and operational efficiency—a catalyst management mentioned but did not emphasize enough given its long-term margin expansion potential. While Q1 EBITDA was only slightly below the prior year ($2.8M vs $2.9M), the segment held gross margin flat at 53.6% year-over-year despite SG&A rising 90 basis points due to professional fees, indicating underlying pricing power and cost discipline. More importantly, the CEO highlighted that they are actively testing and utilizing technology to serve high-touch small- and medium-sized enterprises (SMEs), a segment where personalization and responsiveness command premium pricing. This technological edge is not merely defensive; it is enabling them to win RFPs and build a record pipeline through their newly formed internal sales team, directly addressing historical gaps in sales capacity. The ability to integrate advanced CRM, AI-driven routing, and analytics into their service offering allows them to differentiate beyond basic call handling, creating sticky, high-value contracts that are less susceptible to commoditization. As SMEs increasingly outsource customer-facing functions to specialized providers who can deliver both efficiency and empathy, SGC is positioning itself as a preferred partner—leveraging its scale, technology investments, and sales focus to capture share from fragmented, less sophisticated competitors. This segment’s resilience is further underscored by its minimal direct exposure to tariffs (impact is indirect via customer product costs), meaning its growth trajectory is less hostage to macro swings than the Branded Products or Healthcare Apparel segments. With the $13 million in annualized SG&A savings beginning to flow in Q2, the contact center segment’s already strong margins could expand significantly, turning it into a consistent, high-quality earnings driver that the market is undervaluing amid the noise around tariff-sensitive segments.
SGC’s Branded Products segment faces structural margin erosion that is being masked by temporary cost-saving initiatives and aggressive share buybacks, with management avoiding candid discussion about the unsustainability of relying on price increases to offset tariff impacts in a price-sensitive market. While the CEO claimed they can pass on tariff costs through contractual or PO-by-PO mechanisms, he acknowledged timing issues and noted that customers may substitute to lower-priced items—even if those items still carry high tariffs—effectively neutralizing any potential price recovery. This reveals a critical vulnerability: in commoditized promotional products and uniforms, true pricing power is limited, and the segment’s gross margin collapsed to 32% in Q1 from 36.5% a year ago due to sourcing and customer mix shifts—trends that are unlikely to reverse quickly given persistent macro uncertainty and customer hesitancy. The CFO’s admission that SG&A is being cut by $13 million annualized starting in Q2 to support profitability as “demand normalizes” is a red flag; it implies current operations are unprofitable without these cuts, and the normalization assumption is highly speculative given the open-ended nature of tariff policy and potential for further escalation. Moreover, the company’s reliance on share buybacks ($3.8M in Q1) to bolster EPS while reporting a net loss per share of $0.05 (vs $0.24 prior year) signals financial engineering rather than organic growth, especially when cash flow from operations is being strained by seasonal working capital outflows (evident in the AP and current liabilities decline). The market may be misinterpreting these buybacks as confidence, but they are occurring amid declining core profitability and rising leverage (net leverage up to 2.2x from 1.7x), increasing financial risk if revenue does not rebound as hoped.
The Healthcare Apparel segment’s growth narrative is dangerously overstated, as management’s focus on digital channel expansion ignores the segment’s fundamental dependence on volatile institutional healthcare spending—a driver that is currently impaired by government funding pullbacks and shows no clear near-term recovery path, rendering digital investments premature and potentially wasteful. While management cited investing in digital wholesale and DTC channels to grow their single-digit market share, they conceded that institutional Healthcare Apparel—historically a core revenue driver—is weak due to buyers being in a “wait-and-see” mode on tariffs and experiencing pullbacks in government-funded research (which directly impacts lab coats and protective gear, a notable subset of their product mix). The CEO’s attempt to downplay this by noting scrubs are less affected is insufficient; institutional buyers encompass far more than scrubs, and the segment’s Q1 revenue decline of 7% versus prior year reflects broad-based weakness that digital channels alone cannot offset in the short term. Building DTC and wholesale digital platforms requires sustained investment in marketing, technology, and logistics—costs that are hitting SG&A (up 90 basis points in Healthcare Apparel to 34.9% of sales) without a corresponding revenue uptick, creating a drag on profitability. Worse, the segment’s gross margin, while up sequentially, remains below prior year levels at 37.2% vs 39.4%, indicating that cost pressures are not easing. The market may be betting on a long-term digital transformation, but without a revival in institutional spending—the bedrock of healthcare apparel demand—these efforts risk becoming a costly sideshow that diverts resources from more profitable segments, especially as the company grapples with tariff-induced complexity elsewhere.
SGC’s contact center segment, while currently resilient, is exposed to significant cyclical and competitive risks that management understated by focusing on internal sales team wins and RFP participation without addressing client concentration, pricing pressure, or the potential for AI-driven disruption to erode their high-margin advantage. The CEO highlighted growth from new customers and solid retention but conceded they expect “a little bit of falloff here and there later on in the year” from existing customers—a candid admission of fragility in their base business that contradicts the optimism around pipeline growth. More troubling, the segment’s SG&A as a percentage of revenue rose to 45.1% (up 90 bps) due to increased professional fees, suggesting that scaling the sales force and pursuing new opportunities is coming at a cost that could outpace revenue growth if macro weakness persists. Crucially, the contact center business is not immune to end-market uncertainty: as SMEs cut costs amid inflation and interest rate pressures, they may reduce outsourcing or shift to lower-cost providers, directly threatening SGC’s core clientele. Furthermore, the industry is undergoing rapid transformation via AI and automation—tools that could commoditize basic call handling and undermine the value proposition of SGC’s “high-touch” SMB focus if they fail to innovate beyond incremental tech upgrades. Management’s vague commitment to “testing and utilizing cutting-edge technology” lacks specificity on ROI or competitive differentiation, leaving open the risk that they are investing in solutions that quickly become table stakes rather than sustainable moats. If AI enables competitors to deliver similar service quality at lower cost, SGC’s 53.6% gross margin could compress rapidly, turning what is currently their strongest segment into a victim of secular disruption—especially given their relatively modest scale against larger, tech-forward players in the outsourcing space.
SGC’s Branded Products segment faces structural margin erosion that is being masked by temporary cost-saving initiatives and aggressive share buybacks, with management avoiding candid discussion about the unsustainability of relying on price increases to offset tariff impacts in a price-sensitive market. While the CEO claimed they can pass on tariff costs through contractual or PO-by-PO mechanisms, he acknowledged timing issues and noted that customers may substitute to lower-priced items—even if those items still carry high tariffs—effectively neutralizing any potential price recovery. This reveals a critical vulnerability: in commoditized promotional products and uniforms, true pricing power is limited, and the segment’s gross margin collapsed to 32% in Q1 from 36.5% a year ago due to sourcing and customer mix shifts—trends that are unlikely to reverse quickly given persistent macro uncertainty and customer hesitancy. The CFO’s admission that SG&A is being cut by $13 million annualized starting in Q2 to support profitability as “demand normalizes” is a red flag; it implies current operations are unprofitable without these cuts, and the normalization assumption is highly speculative given the open-ended nature of tariff policy and potential for further escalation. Moreover, the company’s reliance on share buybacks ($3.8M in Q1) to bolster EPS while reporting a net loss per share of $0.05 (vs $0.24 prior year) signals financial engineering rather than organic growth, especially when cash flow from operations is being strained by seasonal working capital outflows (evident in the AP and current liabilities decline). The market may be misinterpreting these buybacks as confidence, but they are occurring amid declining core profitability and rising leverage (net leverage up to 2.2x from 1.7x), increasing financial risk if revenue does not rebound as hoped.
The Healthcare Apparel segment’s growth narrative is dangerously overstated, as management’s focus on digital channel expansion ignores the segment’s fundamental dependence on volatile institutional healthcare spending—a driver that is currently impaired by government funding pullbacks and shows no clear near-term recovery path, rendering digital investments premature and potentially wasteful. While management cited investing in digital wholesale and DTC channels to grow their single-digit market share, they conceded that institutional Healthcare Apparel—historically a core revenue driver—is weak due to buyers being in a “wait-and-see” mode on tariffs and experiencing pullbacks in government-funded research (which directly impacts lab coats and protective gear, a notable subset of their product mix). The CEO’s attempt to downplay this by noting scrubs are less affected is insufficient; institutional buyers encompass far more than scrubs, and the segment’s Q1 revenue decline of 7% versus prior year reflects broad-based weakness that digital channels alone cannot offset in the short term. Building DTC and wholesale digital platforms requires sustained investment in marketing, technology, and logistics—costs that are hitting SG&A (up 90 basis points in Healthcare Apparel to 34.9% of sales) without a corresponding revenue uptick, creating a drag on profitability. Worse, the segment’s gross margin, while up sequentially, remains below prior year levels at 37.2% vs 39.4%, indicating that cost pressures are not easing. The market may be betting on a long-term digital transformation, but without a revival in institutional spending—the bedrock of healthcare apparel demand—these efforts risk becoming a costly sideshow that diverts resources from more profitable segments, especially as the company grapples with tariff-induced complexity elsewhere.
SGC’s contact center segment, while currently resilient, is exposed to significant cyclical and competitive risks that management understated by focusing on internal sales team wins and RFP participation without addressing client concentration, pricing pressure, or the potential for AI-driven disruption to erode their high-margin advantage. The CEO highlighted growth from new customers and solid retention but conceded they expect “a little bit of falloff here and there later on in the year” from existing customers—a candid admission of fragility in their base business that contradicts the optimism around pipeline growth. More troubling, the segment’s SG&A as a percentage of revenue rose to 45.1% (up 90 bps) due to increased professional fees, suggesting that scaling the sales force and pursuing new opportunities is coming at a cost that could outpace revenue growth if macro weakness persists. Crucially, the contact center business is not immune to end-market uncertainty: as SMEs cut costs amid inflation and interest rate pressures, they may reduce outsourcing or shift to lower-cost providers, directly threatening SGC’s core clientele. Furthermore, the industry is undergoing rapid transformation via AI and automation—tools that could commoditize basic call handling and undermine the value proposition of SGC’s “high-touch” SMB focus if they fail to innovate beyond incremental tech upgrades. Management’s vague commitment to “testing and utilizing cutting-edge technology” lacks specificity on ROI or competitive differentiation, leaving open the risk that they are investing in solutions that quickly become table stakes rather than sustainable moats. If AI enables competitors to deliver similar service quality at lower cost, SGC’s 53.6% gross margin could compress rapidly, turning what is currently their strongest segment into a victim of secular disruption—especially given their relatively modest scale against larger, tech-forward players in the outsourcing space.